|
Jun 20
|
Why CareTrust, Merck, And Allete Are Winners For Passive Income
|
|
Jun 19
|
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
|
|
Jun 19
|
2 Reasons to Watch MRK and 1 to Stay Cautious
|
|
Jun 18
|
Why the Market Dipped But Merck (MRK) Gained Today
|
|
Jun 18
|
Merck (NYSE:MRK) Begins Phase 3 Trial Of Innovative Prostate Cancer Treatment
|
|
Jun 18
|
American Kidney Fund Launches Kidney Cancer Education Campaign
|
|
Jun 18
|
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
|
|
Jun 18
|
Dividend Growth Remains a Key Priority for Merck
|
|
Jun 17
|
Exiger CMO Kody Gurfein Wins PRNews' Top Women Award
|
|
Jun 13
|
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
|
|
Jun 13
|
Citizens Financial, Merck, oil producers: Trending Tickers
|
|
Jun 13
|
Investors should be 'embracing volatility'
|
|
Jun 13
|
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
|
|
Jun 13
|
MSD begins Phase III trial of dengue vaccine
|
|
Jun 12
|
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
|
|
Jun 12
|
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
|
|
Jun 11
|
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials
|
|
Jun 11
|
Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
|